Lung Injury
Conditions
Brief summary
Phase 1 study investigating safety of lanadelumab administration to patients with lung injury
Detailed description
This study will investigate the safety of inhibition of plasma kallikrein by lanadelumab administration in patients with lung injury.
Interventions
DRUGLanadelumab
Monoclonal antibody that targets active plasma kallikrein
OTHERSaline control
Saline control
Sponsors
St Vincent's Institute of Medical Research
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open-label placebo-controlled dose-escalation Phase 1 study
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Age \>18 years admitted to the ICU with primary diagnosis of lung injury. The criteria for the diagnosis of lung injury include five principal elements: hypoxemia (blood oxygen saturation (PaO2) ≤92% when breathing ambient air, ratio of PaO2 to the fraction of inspired oxygen (FiO2) ≤300), diffuse pulmonary infiltrates on chest radiographs, decreased lung compliance, and the absence of congestive heart failure. * Both males and females will be recruited in the proportion in which they are admitted to the ICU with lung injury. * Arterial cannula in place as part of usual care for the measurement of blood gases. * Patients may or may not be intubated and mechanically ventilated. * Able to provide informed consent, or if unable to do so, a responsible person: medical treatment decision maker is available (by telephone if necessary) who can be approached to seek consent.
Exclusion criteria
* Other causes of lung infiltrates: pulmonary oedema, alveolar haemorrhage, adverse drug reactions, radiation injury and the idiopathic pneumonitis syndrome. * Significant dysfunction of non-pulmonary organs in the opinion of the treating ICU consultant. * Death is deemed imminent or inevitable or there is underlying disease with a life expectancy of less than 90 days. * Previously enrolled in this study. * Enrolled in another study. * Usually receives home oxygen. * Usually receives any type of assisted ventilation at home. e.g. continuous positive airway pressure for obstructive sleep apnoea. * Pregnant or might be pregnant. Women aged 18 to 49 are excluded unless there is documented menopause, hysterectomy or surgical sterilisation, or a pregnancy test is negative. * Objection from the treating clinician. * Consent refused by the patient or substitute decision maker.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-Related Adverse Events | 28 days | Blood gases, pH, bicarbonate, carbon dioxide and lactic acid levels. If the participant is receiving mechanical ventilation, the ventilator settings will be constantly monitored. Chest X-ray, as indicated. Constant monitoring of haemodynamics (pulse rate, blood pressure) via an arterial cannula, use of vasoactive medications, and constant monitoring of ECG. Fluid balance, including urine output. Serum creatinine, electrolytes, liver function, creatinine kinase, FBE and coagulation will be measured daily or less frequently as decided by the treating team. If there is suspicion of infection, then appropriate samples will be taken for microbiological examination. Neurological function will be assessed several times per day. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood bradykinin concentration | 0, 6, 12, and 24 hours | Blood bradykinin concentration |
Countries
Australia
Outcome results
None listed